Exchange: NASDAQ·Updated 07:59 PM EST
MRKR logo

MRKR Marker Therapeutics Inc

$1.09
$0.23
(17.42%)
Today
Closed $1.09
$0.04
(3.67%)
After Hours
Mkt Cap$18.17M
Vol1.97M

About MRKR

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
67

Bullish Sentiment

How do you feel about MRKR?

Rayvio_News_Filter
$MRKR 🏛️ Marker Therapeutics, Inc. was awarded a $16.2 million CPRIT grant to support Phase 2 development of MT-601 in CAR-relapsed lymphoma.
1
3
BiotechSwings
35.85 million shares and $MRKR normally trades about 121k closed 1.32 Thursday, up 54.7% off a 0.85 close, high at 1.68 Texas handed Marker a 16.2 million dollar grant with no new shares issued that funds MT 601 into a planned Phase 2 APOLLO study in relapsed or refractory large B cell lymphoma after CD19 CAR T Phase 1 showed a 66% response rate there. updated data still due later this year imo
1
2
WarriorSTC
$MRKR $10.00 High Target: Maintained with a Buy rating by H.C. Wainwright across 2026 (including updates in July, August, and September 2026), representing the street-high estimate
5
Stock_Catcher
$MRKR Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study
1
2
plavac
$MRKR Key Dates and Details (ASH 2026) 68th Annual Meeting of the American Society of Hematology • Date and Location: December 12–15, 2026, Ernest N. Morial Convention Center, New Orleans, Louisiana (virtual option available; presenters must be present on-site). • Late Abstract Submission: Closed October 28, 2026 at 11:59 PM PT (six abstracts selected). • Late Abstract Publication: December 7, 2026 online and in Blood. • Late Abstract Presentation: December 15, 2026
4
flashdash
$MRKR ----TINY MARKET CAP for a biotech targeting lymphoma and pancreatic cancer, and working with the BAYLOR COLLEGE of MEDICINE.
3
Bakhm
$MRKR If the FDA and other organizations are awarding them grants, then this company is definitely worth paying attention to.
3
GoIrish1776
$MRKR People are going to wake up one day and realize this product is going to get approved for treatment. This funding is a big deal on the dilution front. Nice work to Dr Vera and team.
3
UKBullTrader
$MRKR continues to just sail upwards. Very pleased. 😀Let’s see how the rest of power hour go and AH should be very interesting indeed.
2
Rmichael4
$MRKR if latest 10Q is correct looks like about $12.5 million (cash & equivalents) and then the Grant announcement this morning of another $16.5 million so $29 million give/take🤷‍♂️ seems like no real urgency to do an offering but I have been wrong many times on these tiny biotechs🤷‍♂️All thoughts and opinions greatly appreciated
2
flashdash
$MRKR ------ A 50% COMPLETE RESPONSE RATE was achieved for non-Hodgkins Lymphoma in the phase 1 $MRKR APOLLO study.
2
DontInvestLikeMe
$MRKR Got out with a little over a 20% win. Better than anything else I have done today, so I will take the green and be happy. Good luck, everyone!
2
CloudGuy
$MRKR Given the excellent news, who the heck has sold 7M shares (out of 16M outstanding) at these prices?
2
Trak2
$MRKR the way the stock price is moving, hopefully news should be coming out soon, maybe somebody knows something. The ash conference is next month, so let’s hope and pray.
2
GTA_Terminal
$MRKR saw 0.7x its normal dark pool volume on Wednesday (Nov 18), 49,000 shares in all and 46.3% of trading (neutral). Against the five-session average of 74,700 shares, Wednesday ranked as the second-lightest. That compares with a five-session average share of 56.2% off-exchange. Source: GTA Terminal from Global Traders Academy.
1
RTPRwire
$MRKR is seeing a strong reaction on contract win following a Globe Newswire release. Marker Therapeutics received a $16.2 million CPRIT grant to advance MT-601 in Phase 2 development for CAR-relapsed lymphoma treatment. RTPR pushed this release out to users at 7:00:00 AM ET
1
JeffFaffa
$MRKR Vera doesn't have to be caught cheating for this ticker to drop - he so ugly, the sp drops on its own
1
Trak2
$MRKR according to AI, if the data is being peer reviewed, it would have been submitted in August, and tomorrow the ash cancer conference will announce the abstracts. otherwise, it was submitted late, and we won’t know till December 7. let’s keep our fingers crossed for tomorrow
1

Advertisement|Remove ads.